Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11078452 | 0.79 | ALOX5 (0.50) | HPGDTP53KDM4EALDH1A1HSD17B10 | |
| SCHEMBL28111436 | 0.79 | SMN1; SMN2 (0.46) | KDM4EALDH1A1MAPK1CA1CA2 | |
| SCHEMBL28007983 | 0.79 | IDO1 (0.44) | HPGDTP53KDM4EALDH1A1HSD17B10 | |
| SCHEMBL1927956 | 0.78 | ALOX12 (0.64) | HPGDTP53KDM4EALDH1A1HSD17B10 | |
| SCHEMBL5759879 | 0.78 | IDO1 (0.47) | HPGDTP53KDM4EALDH1A1HSD17B10 | |
| SCHEMBL12473426 | 0.77 | CA1 (0.55) | HPGDTP53KDM4EALDH1A1HSD17B10 | |
| SCHEMBL31116611 | 0.77 | CA1 (0.61) | HPGDTP53KDM4EALDH1A1HSD17B10 | |
| SCHEMBL357145 | 0.77 | CA1 (0.61) | HPGDTP53KDM4EALDH1A1HSD17B10 | |
| SCHEMBL11220048 | 0.75 | GABRA1 (0.48) | HPGDTP53KDM4EALDH1A1HSD17B10 | |
| SCHEMBL19465429 | 0.75 | KDM4E (0.39) | HPGDKDM4EALDH1A1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4304720-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2023-02-23 | — | — | US | disclosed |
| US-11492351-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-10-25 | — | — | US | disclosed |
| WO-2022192745-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-4028388-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-114728912-A | MTA-synergistic PRMT5 inhibitors | 米拉蒂医疗股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210079003-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | disclosed |
| US-20210078994-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | disclosed |
| WO-2021050915-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050915-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | HPGD 2337/4885TP53 263/4885KDM4E 143/4885 |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT1, PRMT5, PRMT6 | HPGD 3263/4885TP53 603/4885KDM4E 644/4885 |
| US-20210079003-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | HPGD 2554/4885TP53 161/4885KDM4E 122/4885 |
| US-20210078994-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | HPGD 2554/4885TP53 161/4885KDM4E 122/4885 |
| US-11492351-B2 | MTA-cooperative PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | HPGD 2337/4885TP53 263/4885KDM4E 143/4885 |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | HPGD 2554/4885TP53 161/4885KDM4E 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.